JPMorgan Chase released a research report noting that the previous day (20th), China's National Healthcare Security Administration issued the "Guidelines for Establishing Price Items for Pathological Medical Services (Trial)" and held a policy briefing in Beijing. The market reaction was notably positive, with MEDBOT-B's (02252) stock price surging approximately 15% following the announcement, reflecting increased visibility for its reimbursement mechanism and a clearer commercial pathway. The bank maintains an "Overweight" rating on MEDBOT with a target price of HK$42.

The report suggests these guidelines have a structurally positive impact on China's surgical robot market, establishing a consistent charging pathway while promoting an industry shift towards value-based and tiered reimbursement models. According to the guidelines, each province will set price floors and ceilings for services related to surgical robots. Crucially, the guidelines explicitly define three pricing tiers for robotic-assisted surgeries, allowing more powerful and precise robots to command higher fees for procedures.

JPMorgan believes this move will support broader clinical adoption of surgical robots and encourage the development and utilization of advanced robotic systems.